Viral Long Noncoding RNA Functions in Epstein-Barr Virus Infection
病毒长非编码 RNA 在 Epstein-Barr 病毒感染中的功能
基本信息
- 批准号:8806522
- 负责人:
- 金额:$ 37.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-01 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdoptionB-LymphocytesCCCTC-binding factorCellsCellular ImmunityChromatinChromatin LoopComplexControl LocusDNA replication originDataDevelopmentDiseaseDistalEpstein-Barr Virus InfectionsEpstein-Barr Virus latencyEquilibriumEventGene DuplicationGene ExpressionGenesGenetic TranscriptionGenomeHerpesviridaeHumanHuman Herpesvirus 4ImmuneIndividualInfectionInfectious MononucleosisIntronsKnowledgeLifeLocationLymphomaLymphoproliferative DisordersLytic PhaseMaintenanceMalignant NeoplasmsMediatingMedicalMemory B-LymphocyteMessenger RNAMicroRNAsMolecular ConformationNucleotidesOncogenicPatientsPatternPlayProcessPropertyProtein BindingProteinsRNARNA SplicingRecombinantsRegulationResearchRestRisk FactorsRoleSmall Nucleolar RNATestingTranscriptUntranslated RNAViralViral GenesViral GenomeViral ProteinsVirusVirus LatencyVirus Replicationcofactordefined contributionimmunosuppressedlatency-associated proteinlatent infectionparalogous genepathogenpersistent EBV infectionprogramspromoterprotein expressionpublic health relevancetraffickingviral RNA
项目摘要
DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is an extremely successful pathogen, being able to establish a lifelong latent infection within B lymphocytes of its human host, with overt disease in healthy individuals restricted to a self- limiting mononucleosis in ~40% of individuals when infection is delayed until the second decade of life. However, a breakdown in cellular immunity, particularly as a consequence of AIDS, remains a significant risk factor for development of EBV-associated lymphoma and lymphoproliferative disease, underscoring the highly evolved equilibrium that exists between EBV and its host. Establishment of this equilibrium, and EBV's oncogenic potential are dependent on a highly coordinated and controlled expression of the EBV latency- associated genes, which encode not only proteins but at least four classes of noncoding RNAs (ncRNAs). The long-term objective of the research proposed in this application is to understand the contributions made to EBV infection and pathogenic potential by two EBV RNAs belonging to the class of long ncRNAs (lncRNAs), i.e., RNAs longer than 200 nucleotides with little or no functional protein-encoding capability. These lncRNAs are encoded by the paralogous EBV genes BHLF1 and LF3, long known to be expressed at high level during the virus replication or lytic cycle, but recently identified as beig actively expressed during latent infection as well. Our preliminary results indicate that, upon deletion of the BHLF1 locus from the EBV genome, the virus is unable to sustain full expression of the EBV latency-associated proteins, converting to a more restricted program of latency-gene expression associated with long-term EBV persistence within its cellular reservoir, the memory B cell. Thus, we hypothesize that the BHLF1 lncRNA, and its paralog from LF3, play active but distinct roles in the regulation of EBV latent infection and persistence. We propose four specific aims: Under Aim 1, we will identify proteins that interact with the BHLF1 lncRNA, and the role that these specific RNA:protein associations play in EBV latent infection. In Aim 2 we will elucidate the expression patterns of the BHLF1 lncRNAs during the different EBV latency programs (defined by specific patterns of viral gene expression), and whether they traffic to specific subcellular domains with known functionality, possibly revealing function(s) of the EBV lncRNA. In Aim 3 we will elucidate whether the BHLF1 gene locus itself, in concert with its lncRNA, acts as a central determinant of EBV latency program by regulating viral genome configuration and other mechanisms. Finally, under Aim 4 we will begin to define the roles that the LF3 locus and lncRNA contribute to EBV latency, taking a similar tack as we have proposed for BHLF1.
描述(由申请人提供):eb病毒(EBV)是一种非常成功的病原体,能够在其人类宿主的B淋巴细胞内建立终身潜伏感染,在健康个体中,当感染延迟到生命的第二个十年时,约40%的个体的显性疾病仅限于自限性单核细胞增生。然而,细胞免疫功能的崩溃,特别是艾滋病的后果,仍然是eb病毒相关淋巴瘤和淋巴细胞增生性疾病发展的重要危险因素,强调了eb病毒与其宿主之间存在高度进化的平衡。这种平衡的建立和EBV的致癌潜能依赖于EBV潜伏期相关基因的高度协调和控制表达,这些基因不仅编码蛋白质,还编码至少四类非编码rna (ncrna)。本申请中提出的研究的长期目标是了解两种EBV rna对EBV感染的贡献和致病潜力,这些rna属于长ncRNAs (lncRNAs)类别,即长度超过200个核苷酸的rna,很少或没有功能性蛋白质编码能力。这些lncrna由相似的EBV基因BHLF1和LF3编码,长期以来人们都知道BHLF1和LF3在病毒复制或裂解周期中高水平表达,但最近发现它们在潜伏感染期间也积极表达。我们的初步结果表明,从EBV基因组中删除BHLF1位点后,病毒无法维持EBV潜伏期相关蛋白的完全表达,而在其细胞储存库(记忆B细胞)中转化为与EBV长期持久性相关的更受限制的潜伏期基因表达程序。因此,我们假设BHLF1及其LF3同源lncRNA在EBV潜伏性感染和持久性的调控中发挥积极但不同的作用。我们提出了四个具体目标:在目标1中,我们将鉴定与BHLF1 lncRNA相互作用的蛋白质,以及这些特定RNA:蛋白质关联在EBV潜伏感染中发挥的作用。在Aim 2中,我们将阐明BHLF1 lncRNA在不同EBV潜伏期程序(由病毒基因表达的特定模式定义)中的表达模式,以及它们是否传输到具有已知功能的特定亚细胞结构域,从而可能揭示EBV lncRNA的功能。在Aim 3中,我们将阐明BHLF1基因位点本身及其lncRNA是否通过调节病毒基因组结构和其他机制,作为EBV潜伏期程序的中心决定因素。最后,在Aim 4中,我们将开始定义LF3位点和lncRNA对EBV潜伏期的作用,采取与我们对BHLF1提出的类似的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFERY T SAMPLE其他文献
JEFFERY T SAMPLE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFERY T SAMPLE', 18)}}的其他基金
Viral Long Noncoding RNA Functions in Epstein-Barr Virus Infection
病毒长非编码 RNA 在 Epstein-Barr 病毒感染中的功能
- 批准号:
8659714 - 财政年份:2014
- 资助金额:
$ 37.17万 - 项目类别:
Viral Long Noncoding RNA Functions in Epstein-Barr Virus Infection
病毒长非编码 RNA 在 Epstein-Barr 病毒感染中的功能
- 批准号:
9017925 - 财政年份:2014
- 资助金额:
$ 37.17万 - 项目类别:
Mechanisms of Gene Regulation by EBV EBNA-1 Protein
EBV EBNA-1蛋白的基因调控机制
- 批准号:
7621316 - 财政年份:2009
- 资助金额:
$ 37.17万 - 项目类别:
Mechanisms of Gene Regulation by EBV EBNA-1 Protein
EBV EBNA-1蛋白的基因调控机制
- 批准号:
7847575 - 财政年份:2009
- 资助金额:
$ 37.17万 - 项目类别:
Mechanisms of Gene Regulation by EBV EBNA-1 Protein
EBV EBNA-1蛋白的基因调控机制
- 批准号:
7681398 - 财政年份:2008
- 资助金额:
$ 37.17万 - 项目类别:
相似海外基金
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 37.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 37.17万 - 项目类别:
Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 37.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 37.17万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 37.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 37.17万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 37.17万 - 项目类别:
Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 37.17万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 37.17万 - 项目类别:
EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 37.17万 - 项目类别:
Standard Grant